Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Combinations May Confer Benefit in MDS Management

October 11th 2018

Mikkael A. Sekeres, MD, discusses the characteristics of myelodysplastic syndrome and the evolving armamentarium of treatment.

Zonder Addresses Unanswered Questions in Newly Diagnosed Myeloma

October 10th 2018

Jeffrey A. Zonder, MD, discusses triplet regimens in multiple myeloma and patient eligibility for clinical trials.

Dr. Verstovsek on Accelerated Phase Myelofibrosis

October 10th 2018

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses accelerated phase myelofibrosis.

Dr. Wong on a Trial With an Anti-CD46 Antibody in Myeloma

October 10th 2018

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses a trial with an anti-CD46 antibody in multiple myeloma.

Individualized Regimens Instrumental After Early Relapse in Myeloma

October 9th 2018

Michael Green, MD, discusses treatment strategies following early relapse in multiple myeloma.

Dr. Shah Discusses Frontline Considerations for the Treatment of CML

October 5th 2018

Neil Shah, MD, PhD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco (UCSF) Program Leader, Hematopoietic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses frontline treatment considerations for patients with chronic myeloid leukemia.

Damon Discusses Drug Development in AML

October 5th 2018

Lloyd Damon, MD, discusses novel therapies in acute myeloid leukemia, including FLT3 and IDH1/2 inhibitors.

Expert Discusses Transplant and Emerging Strategies in Myeloma

October 5th 2018

Thomas G. Martin, MD, discusses the clinical utility of autologous stem cell transplantation and the rapidly evolving treatment paradigm of myeloma.

Dr. Yacoub on Pegylated Interferon Treatment for PV

October 4th 2018

Abdulraheem Yacoub, MD, associate professor of medicine, University of Kansas Medical Center, discusses the potential of pegylated interferon treatment in patients with polycythemia vera.

Treatment Discontinuation Achievable in Select Patients With CML

October 4th 2018

Ehab Atallah, MD, discusses the discontinuation of treatment for patients with chronic myeloid leukemia.

Dr. Green on Early Relapse in Multiple Myeloma

October 4th 2018

Michael Green, MD, Northern California Oncologist, discusses early relapse in multiple myeloma.

Dr. Raje on Quadruplet Regimens in Myeloma

October 1st 2018

Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, discusses the potential of quadruplet regimens in the multiple myeloma treatment paradigm.

Dr. Deol on the Safety of CAR T-Cell Therapy

September 28th 2018

Abhinav Deol, MD, associate professor with Karmanos Cancer Institute, discusses patient eligibility for chimeric antigen receptor (CAR) T-cell therapy in hematologic oncology.

Dr. Radich on Treatment Discontinuation in CML Off Trial

September 28th 2018

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses treatment discontinuation off trial for patients with chronic myeloid leukemia (CML).

Expert Shares Insight on Impact of Bone Marrow Transplant on MDS Paradigm

September 27th 2018

Joseph Uberti, MD, PhD, discusses the risk and benefit of a bone marrow transplant for patients with myelodysplastic syndrome.

Future AML Advancements Include Next-Generation Targeted Therapies

September 27th 2018

Jay Yang, MD, explains that drug development is not as simple as identifying a molecular target and matching inhibitor.

Dr. Michaelis Discusses the JAK2 Mutation in MPNs

September 26th 2018

Laura Michaelis, MD, associate professor of medicine, Medical College of Wisconsin, discusses implications for the JAK2 mutation in patients with myeloproliferative neoplasms.

Dr. Yang on the Future of Acute Myeloid Leukemia

September 26th 2018

Jay Yang, MD, oncologist, Barbara Ann Karmanos Cancer Institute, discusses the future of acute myeloid leukemia (AML).

Expert Recaps Advances in AML

September 26th 2018

Rami S. Komrokji, MD, reflects on the diverse acute myeloid leukemia treatment landscape and touches on the prognostic importance of biomarkers.

Dr. Zonder on Induction Therapy in Newly Diagnosed Multiple Myeloma

September 26th 2018

Jeffrey Zonder, MD, associate professor of oncology and medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses induction therapy in the treatment of patients with newly diagnosed multiple myeloma.